Fig. 2

TRPM3 activity after ononetin modulation. Data were obtained under whole-cell patch-clamp conditions. A A representative time-series of current amplitude at + 100 mV and − 100 mV showing the effect of 10 μΜ ononetin on ionic currents in the presence of PregS in isolated NK cells from HC. B I–V before and after application of ononetin in a cell as shown in (A). C Scatter plots representing change of each current amplitude before and after application of ononetin in presence of PregS in all NK cells from HC. D A representative time-series of current amplitude at + 100 mV and − 100 mV showing the effect of 10 μΜ ononetin on ionic currents in the presence of PregS in isolated NK cells ME/CFS patients. E I–V before and after application of ononetin in a cell as shown in (D). F Scatter plots representing change of each current amplitude before and after application of ononetin in presence of PregS in all NK cells from ME/CFS. G A representative time-series of current amplitude at + 100 mV and − 100 mV showing the effect of 10 μΜ ononetin on ionic currents in the presence of PregS in isolated NK cells from post COVID-19 condition. H I–V before and after application of ononetin in a cell as shown in (G). I Scatter plots representing change of each current amplitude before and after application of ononetin in presence of PregS in all NK cells from post COVID-19 condition. Each cell represented as red lines indicate cells sensitive to ononetin as a reduction in amplitude was recorded. HC (N = 5; n = 29), post COVID-19 condition (N = 5; n = 27), and ME/CFS (N = 5; n = 23). N to number of participants and n to number of records analysed. HC healthy controls, ME/CFS myalgic encephalomyelitis/chronic fatigue syndrome